ACE inhibitors vs ARBs: Is one class better for heart failure

Mark E. Dunlap, MD
Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio

Ross C. Peterson, MD
University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio

Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail med3@po.cwru.edu

Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Mark E. Dunlap, MD
Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio

Ross C. Peterson, MD
University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio

Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail med3@po.cwru.edu

Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Mark E. Dunlap, MD
Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio

Ross C. Peterson, MD
University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio

Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail med3@po.cwru.edu

Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.